











# **COVID-19 Vaccines : Pharmacovigilance national strategies and challenges in Morocco**

**Training of Trainers course on vaccine safety and effectiveness  
- 15 march 2021 -**

**Dr Saadia SKALLI  
Clinical Pharmacist  
- Morocco -**

# COVID-19 Vaccines in Morocco :

## Comparaison de certains vaccins du Covid-19

Société	Type	Doses	Quelle efficacité	Conservation
 <b>Oxford Uni-AstraZeneca</b>	Vecteur viral (virus génétiquement modifié)	x2 	70.4%	2 à 8C (6 mois)
 <b>Moderna</b>	ARN (partie du code génétique du virus)	x2 	94.10%	-25 à 15C (7 mois)
 <b>Pfizer-BioNTech</b>	ARN	x2 	95%	de -80 à -60C (6 mois)
 <b>Gamaleya (Sputnik V)</b>	Vecteur viral	x2 	91.4%*	-18.5C (forme liquide) 2 à 8°C (forme sèche)
 <b>Sinovac (CoronaVac)</b>	Virus inactivé (virus affaibli)	x2 	50.4 - 78%*	2 à 8C

\*données préliminaires, non encore examinées par les pairs

Source : Gouvernement britannique, Reuters

BBC

- Mass immunization operation: 30th january 2021
- > 2880 vaccination stations
- First vaccinated : healthcare Professional, > 65 years-old

18h00 - 12/03/2021

Nombre de personnes vaccinées :



Dose 1:


4 169 133



Dose 2:

1 224 959

# Assessing the Safety of COVID-19 Vaccines : 4 Key Points

1. COVID-19 vaccines developed at an unprecedented speed :
    - A Huge Number of people vaccinated because of health crisis
    - No DNA or RNA vaccines licensed in humans before
    - Concerns about adequate safety assessments
  2. Many entities tasked with assessing and monitoring vaccine safety at national levels and prior experience in enhanced vaccine safety activities
  3. Tools to intensively monitor and assess the safety of COVID-19 vaccines are deployed :
    - Coordination and collaboration with patients and healthcare Professional
    - Robust public safety surveillance monitoring to protect public health
  4. Challenges for the Safe and Responsible Deployment of COVID-19 Vaccines
- 

## Key point 2 :

Many entities tasked with assessing and monitoring vaccine safety at national levels



## Key point 3 : Tools to intensively monitor and assess safety of COVID-19 vaccines

1. Workflow for Patient
2. Workflow for Healthcare Professional

# Workflow for Patient

Bienvenue sur le portail de la  
campagne de **vaccination**  
contre le coronavirus

18h00 - 12/03/2021

Nombre de personnes vaccinées :

 Dose 1: **4 169 133**  Dose 2: **1 224 959**



Le vaccin contre le coronavirus

Me protéger, protéger mon pays

GUIDE RAPIDE D'UTILISATION DE  
**YAKADALIQA**  
POUR LES PERSONNES AYANT REÇU  
LE VACCIN CONTRE LE CORONAVIRUS



je m'informe sur  
mon RDV de  
vaccination / je  
change mon  
adresse →



Je déclare un  
événement  
indésirable suite à ma  
vaccination →




Je télécharge mon  
certificat de  
vaccination →



[illegible]

# Workflow for Healthcare Professional



Consulter Dossier Patient pour déclarer une fiche MAPI

MAPI immédiate Historique MAPI

RECHERCHE PATIENT

Saisir son numéro de téléphone

Lancer la recherche





# Key point 4 : National vaccination Challenges involving PV

To ensure vaccine safety: exhaustive collection of AEFI, data analysis to react early  
To undertake robust and early signals verification and post-licensure studies on safety.



- Obligation to report adverse events following the Covid-19 vaccine, and Deployment of national AEFI reporting app : yakadaliqah.ma
- Designation of PV focal point at regional levels
- Role of doctors in vaccination centers
- Designation of expert groups in each hospital
- Organization of the monitoring of AEFI at regional and national level

Training and capacity building for vaccine vigilance  
Reorganization of the national PV work

**Thank you for your attention**